Improving engineered T cell therapy for pancreatic cancer
Enhancing engineered T cell therapeutic efficacy for the treatment of pancreatic ductal adenocarcinoma
['FUNDING_R01'] · UNIVERSITY OF MINNESOTA · NIH-11143879
A new engineered T cell approach aims to attack pancreatic cancer and its protective tumor environment to help people with advanced pancreatic cancer.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF MINNESOTA (nih funded) |
| Locations | 1 site (MINNEAPOLIS, UNITED STATES) |
| Trial ID | NIH-11143879 on ClinicalTrials.gov |
What this research studies
This project engineers T cells to recognize mesothelin, a protein commonly found on pancreatic tumor cells, and tests how well those T cells penetrate and act within tumors. Experiments are done in animal models that mimic human pancreatic ductal adenocarcinoma to observe tumor shrinkage, changes in the surrounding stromal tissue, and effects on immune-suppressive cells. Researchers measure which T cell properties lead to stronger anti-tumor responses and longer survival in these models. Results are intended to guide development of safer and more effective T cell therapies that could move toward human testing.
Who could benefit from this research
Good fit: People with advanced or metastatic pancreatic ductal adenocarcinoma whose tumors express mesothelin and who are eligible for experimental cellular therapies would be the most relevant candidates.
Not a fit: Patients whose tumors lack mesothelin expression or who are medically unfit for adoptive cell therapy may not benefit from this approach.
Why it matters
Potential benefit: If successful, this approach could lead to more effective T cell immunotherapies that shrink pancreatic tumors and extend survival.
How similar studies have performed: Engineered T cell therapies have shown strong benefits in some blood cancers and early preclinical or early-phase work targeting mesothelin has been promising, but pancreatic tumors remain particularly challenging.
Where this research is happening
MINNEAPOLIS, UNITED STATES
- UNIVERSITY OF MINNESOTA — MINNEAPOLIS, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: STROMNES, INGUNN MARGARETE — UNIVERSITY OF MINNESOTA
- Study coordinator: STROMNES, INGUNN MARGARETE
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Advanced Cancer